Conference Reports for NATAP

66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13-17 2015 Back

C-EDGE Co-infection: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742)/Grazoprevir (GZR, MK-5172) on Patient-Reported Outcomes (PROs) in Treatment- Naïve Patients With HCV/HIV Co-infection       Reported by Jules Levin AASLD 2015 Nov 13-17 San Francisco   Jean Marie Arduino; Zhiwei Jiang; Melissa Shaughnessy; Shazia Khawaja; Elisa Martinez; Heather Platt; Chizoba Nwankwo; T. Christopher Mast Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA